Tessa Romero
Stock Analyst at JP Morgan
(3.83)
# 654
Out of 4,962 analysts
66
Total ratings
46%
Success rate
12.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Maintains: Overweight | $40 → $30 | $14.85 | +102.02% | 9 | Aug 19, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $30 → $34 | $25.74 | +32.09% | 9 | Jul 24, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $10 → $9 | $12.58 | -28.46% | 6 | Jul 15, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $68 → $55 | $15.61 | +252.34% | 7 | Jun 18, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $38.34 | +38.24% | 5 | Jun 9, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Overweight | $16 → $10 | $4.90 | +104.08% | 2 | May 30, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $17.63 | +115.54% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $1.62 | +825.93% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $19.44 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $35.49 | -12.65% | 5 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $11.83 | +145.14% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $46 | $38.80 | +18.56% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $8.53 | -17.94% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $38.84 | +41.61% | 2 | Apr 25, 2023 |
Edgewise Therapeutics
Aug 19, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $14.85
Upside: +102.02%
ACADIA Pharmaceuticals
Jul 24, 2025
Maintains: Overweight
Price Target: $30 → $34
Current: $25.74
Upside: +32.09%
Dyne Therapeutics
Jul 15, 2025
Maintains: Neutral
Price Target: $10 → $9
Current: $12.58
Upside: -28.46%
Biohaven
Jun 18, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $15.61
Upside: +252.34%
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $38.34
Upside: +38.24%
Lexeo Therapeutics
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $4.90
Upside: +104.08%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $17.63
Upside: +115.54%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $1.62
Upside: +825.93%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $19.44
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $35.49
Upside: -12.65%
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $11.83
Upside: +145.14%
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $38.80
Upside: +18.56%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $8.53
Upside: -17.94%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $38.84
Upside: +41.61%